HSIC Stock Likely to Gain From Its Latest Acquisition of Acentus

Henry Schein, Inc. (HSIC) recently entered into an agreement to acquire Acentus, a national medical supplier that specializes in delivering Continuous Glucose Monitors (CGMs). Henry Schein anticipates the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter. The transaction is expected to be completed in the first quarter of 2025. Financial terms have not been disclosed.HSIC’s Likely Stock Trend Following the NewsFollowing the announcement, shares of HSIC moved south 1.5% t ...